Canaccord maintains $180 target on Natera stock post-NCCN update
Canaccord Genuity maintained a Buy rating on Natera (NASDAQ:NTRA) shares, with a price target of $180. Trading at $169.27, the $22.35 billion market cap company enjoys strong analyst support, with a ...
Cochrane12h
Does giving chemotherapy before surgery improve survival or quality of life in women with advanced epithelial ovarian cancer?
Traditionally, chemotherapy was given after surgery (primary cytoreductive surgery (PCRS) and adjuvant chemotherapy). However, chemotherapy can be used before surgery (neoadjuvant chemotherapy (NACT) ...
Natera comments on updated NCCN guidance for circulating tumor DNA
Natera (NTRA) commented on recent updates by the NCCN on circulating tumor DNA molecular residual disease testing in the Clinical Practice ...
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) molecular residual disease (MRD) ...
Cancer Therapy Advisor21h
Adjuvant Chemo Does Not Improve BCSS in Stage IA HER2+ Breast Cancer Patients With Smaller Tumors
Patients with stage IA HER2+ breast cancer and smaller tumors had high BCSS rates whether they received adjuvant chemotherapy or not.
Cancer Therapy Advisor21h
Personalized Cancer Vaccine Demonstrates Activity in RCC
A neoantigen-targeting personalized cancer vaccine may be effective as adjuvant therapy in patients with high-risk clear cell renal cell carcinoma, phase 1 data suggest.